National Cancer Institute; Notice of Closed Meetings, 80322-80323 [2023-25490]
Download as PDF
<![CDATA[
80322
Federal Register / Vol. 88, No. 221 / Friday, November 17, 2023 / Notices
Dated: November 14, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2023–25464 Filed 11–16–23; 8:45 am]
National Cancer Institute; Notice of
Closed Meetings
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Neurodegenerative Disorders and Aging.
Date: December 6, 2023.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jessica Bellinger, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3158,
Bethesda, MD 20892, (301) 827–4446,
bellingerjd@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 14, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–25465 Filed 11–16–23; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:57 Nov 16, 2023
Jkt 262001
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel Clinical
Trials Planning Program.
Date: January 23, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W106, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Eduardo Emilio Chufan,
Ph.D. Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W106, Rockville, Maryland
20850 240–276–7975, chufanee@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Metastasis
Research Network (U01).
Date: February 1, 2024.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W606, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Bruce Daniel Hissong,
Ph.D. Scientific Review Officer, Resource and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W606 Rockville, Maryland 20850,
240–276–7752, bruce.hissong@nih.gov.
Name of Committee: National Cancer
Institute, Special Emphasis Panel, Diet, Lipid
Metabolism, and Tumor Growth and
Progression.
Date: February 1, 2024.
Time: 9:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W248, Rockville, Maryland 20850 (Virtual
Meeting).
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Contact Person: Shree Ram Singh, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W248, Rockville,
Maryland 20850, 240–672–6175, singhshr@
mail.nih.gov.
Name of Committee: National Cancer
Institute, Special Emphasis, Panel SEP–4:
NCI Clinical and Translational Cancer
Research.
Date: February 6–7, 2024.
Time: 10:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W264, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: Ombretta Salvucci,
Ph.D.,Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W264,
Rockville, Maryland 20850, 240–276–7286,
salvucco@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis, Panel SEP–1: NCI
Clinical and Translational Cancer Research.
Date: February 7, 2024.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W108, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: Clifford W. Schweinfest,
Ph.D., Scientific Review Officer, Special
Review Branch Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W108,
Rockville, Maryland 20850, 240–276–6343,
schweinfestcw@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, NCI SPORE
(P50) Review SEP–I.
Date: February 15–16, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W244, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: John Paul Cairns, Ph.D.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W244,
Rockville, Maryland 20850, 301–461–0303,
paul.cairns@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel NCI
Outstanding Investigator Award (R35).
Date: February 15–16, 2024.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W104, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: David G. Ransom, Ph.D.,
Chief, Scientific Review Officer, Special
E:\FR\FM\17NON1.SGM
17NON1
Federal Register / Vol. 88, No. 221 / Friday, November 17, 2023 / Notices
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W104,
Rockville, Maryland 20850, 240–276–6351,
david.ransom@nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group, Transition to
Independence Study Section (I).
Date: February 15–16, 2024.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W602 Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: Delia Tang, M.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W602, Rockville, Maryland 20850,
240–276–6456. tangd@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, SEP–10:
NCI Clinical and Translational Cancer
Research.
Date: February 22–23, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W606, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: Bruce Daniel Hissong,
Ph.D., Scientific Review Officer, Resource
and Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W606 Rockville, Maryland 20850,
240–276–7752. bruce.hissong@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 14, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–25490 Filed 11–16–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
khammond on DSKJM1Z7X2PROD with NOTICES
Substance Abuse and Mental Health
Services Administration
Notice of Meeting; Correction
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice; correction.
AGENCY:
The Substance Abuse and
Mental Health Services Administration
SUMMARY:
VerDate Sep<11>2014
18:57 Nov 16, 2023
Jkt 262001
(SAMHSA) published a document in the
Federal Register of October 17, 2023, in
FR Doc. 2023–22797 announcing the
meeting of the SAMHSA Center for
Substance Abuse Prevention (CSAP)
Drug Testing Advisory Board (DTAB) on
December 5, 2023, and to request
comments on editing the Authorized
Drug Testing Panels for federally
regulated testing. The document was
revised to reflect new information under
the Supplementary Section.
FOR FURTHER INFORMATION CONTACT: Lisa
Davis, Division of Workplace Programs,
SAMHSA/CSAP, 5600 Fishers Lane,
Rockville, MD 20857, (240) 276–1440
(voice), Lisa.Davis@samhsa.hhs.gov
(email).
SUPPLEMENTARY INFORMATION:
Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given that the
Substance Abuse and Mental Health
Services Administration’s (SAMHSA)
Center for Substance Abuse Prevention’s
(CSAP) Drug Testing Advisory Board
(DTAB) will convene via web
conference on December 5, 2023, from
10:00 a.m. EST to 4:30 p.m.
The board will meet in open-session
December 5, 2023, from 10:00 a.m. EST
to 4:30 p.m. EST to hear Federal Partner
updates and presentations regarding
National Laboratory Certification
Program (NLCP) activities, updates to
the Medical Review Officer (MRO)
Guidance Manual, laboratory-created
cannabinoids and other contaminants in
commercially available products, and
the process for adding or removing
analytes from the Authorized Drug
Testing Panels for federally regulated
testing. The Board will discuss the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs and
revisions to the Authorized Drug
Testing Panels for Urine and Oral Fluid
to add fentanyl and (for urine) norfentanyl, and to remove
methylenedioxymethamphetamine
(MDMA) and
methylenedioxyamphetamine (MDA).
Additionally, the Department is asking
for public comments on these
recommended changes to the drug
testing panel.
Section 8105 of the Fighting Opioid
Abuse in Transportation Act, included
in the SUPPORT for Patients and
Communities Act, required the
Secretary to determine whether it is
justified, based on the reliability and
cost-effectiveness of testing, to revise
the Mandatory Guidelines for Federal
Workplace Drug Testing Programs to
include fentanyl. Section 8105
additionally required the Secretary to
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
80323
consider whether to include any other
drugs or other substances listed in
Schedule I and II of Controlled
Substances Act (CSA). Norfentanyl is a
metabolite of fentanyl. Because it is also
an immediate precursor used in the
illicit manufacture of fentanyl, it is a
Schedule II substance under the CSA.
Fentanyl accounts for a large
proportion of overdose deaths in the
United States and is therefore an
important public safety concern.
Furthermore, fentanyl is increasingly
used as a stand-alone substance of
abuse, not in conjunction with heroin
and other substances. According to the
National Forensic Laboratory
Information System (NFLIS) 2021
report, fentanyl was the 4th most
frequently identified drug and
accounted for 11.61% of all drugs
reported by forensic laboratories.1
Norfentanyl is an important component
of identifying fentanyl users when urine
is the specimen matrix. Fentanyl has
been detected in oral fluid in pain
management patients, overdose cases,
and driving under the influence of drugs
(DUID) cases. Information provided by
HHS-certified laboratories in 2023
indicated that a majority (84%) of the
laboratories analyzed non-regulated
workplace specimens for fentanyl and/
or norfentanyl, and that all had the
ability to analyze urine specimens for
fentanyl with sufficiently sensitive
detection limits using commercially
available immunoassay kits and
confirmatory test instrumentation
commonly used in HHS-certified
laboratories.
The Division of Workplace Programs
welcomes public comment prior to the
DTAB meeting regarding the possible
addition of fentanyl to the Authorized
Drug Testing Panels for Urine and Oral
Fluid. Please see below for the process
to submit comments.
Addition to HHS Drug Testing Panels
as listed below:
Urine analyte
Initial test
cutoff
Fentanyl ............
Norfentanyl .......
1 ng/mL ......
1 ng/mL ......
Oral fluid
analyte
Initial test
cutoff
Fentanyl ............
1 ng/mL ......
Confirmation
cutoff
0.5 ng/mL.
0.5 ng/mL.
Confirmation
cutoff
0.5 ng/mL.
Remove Methylenedioxyamphetamine
(MDA) and
Methylenedioxymethamphetamine
(MDMA) from the Authorized Drug
Testing Panel:
The Department plans to remove
MDA and
E:\FR\FM\17NON1.SGM
17NON1
]]>Agencies
[Federal Register Volume 88, Number 221 (Friday, November 17, 2023)]
[Notices]
[Pages 80322-80323]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-25490]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel Clinical Trials Planning Program.
Date: January 23, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W106, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Eduardo Emilio Chufan, Ph.D. Scientific Review
Officer, Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W106, Rockville, Maryland 20850 240-276-7975,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel, Metastasis Research Network (U01).
Date: February 1, 2024.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W606, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Bruce Daniel Hissong, Ph.D. Scientific Review
Officer, Resource and Training Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W606 Rockville, Maryland 20850, 240-276-7752,
[email protected].
Name of Committee: National Cancer Institute, Special Emphasis
Panel, Diet, Lipid Metabolism, and Tumor Growth and Progression.
Date: February 1, 2024.
Time: 9:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W248, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Shree Ram Singh, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W248, Rockville, Maryland 20850, 240-672-6175,
[email protected].
Name of Committee: National Cancer Institute, Special Emphasis,
Panel SEP-4: NCI Clinical and Translational Cancer Research.
Date: February 6-7, 2024.
Time: 10:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W264, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: Ombretta Salvucci, Ph.D.,Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W264, Rockville, Maryland 20850, 240-276-7286,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis,
Panel SEP-1: NCI Clinical and Translational Cancer Research.
Date: February 7, 2024.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W108, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: Clifford W. Schweinfest, Ph.D., Scientific
Review Officer, Special Review Branch Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W108, Rockville, Maryland 20850, 240-276-6343,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel, NCI SPORE (P50) Review SEP-I.
Date: February 15-16, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W244, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: John Paul Cairns, Ph.D., Scientific Review
Officer, Research Programs Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W244, Rockville, Maryland 20850, 301-461-0303,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel NCI Outstanding Investigator Award (R35).
Date: February 15-16, 2024.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W104, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: David G. Ransom, Ph.D., Chief, Scientific Review
Officer, Special
[[Page 80323]]
Review Branch, Division of Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive, Room 7W104, Rockville,
Maryland 20850, 240-276-6351, [email protected].
Name of Committee: National Cancer Institute Initial Review
Group, Transition to Independence Study Section (I).
Date: February 15-16, 2024.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W602 Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: Delia Tang, M.D., Scientific Review Officer,
Resources and Training Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W602, Rockville, Maryland 20850, 240-276-6456.
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel, SEP-10: NCI Clinical and Translational Cancer Research.
Date: February 22-23, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W606, Rockville, Maryland 20850, (Virtual
Meeting).
Contact Person: Bruce Daniel Hissong, Ph.D., Scientific Review
Officer, Resource and Training Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W606 Rockville, Maryland 20850, 240-276-7752.
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: November 14, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-25490 Filed 11-16-23; 8:45 am]
BILLING CODE 4140-01-P
